Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Behcet Disease - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Behcet Disease - Pipeline Review, H1 2016', provides an overview of the Behcet Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Behcet Disease - The report reviews pipeline therapeutics for Behcet Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Behcet Disease therapeutics and enlists all their major and minor projects - The report assesses Behcet Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Behcet Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Behcet Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Behcet Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Behcet Disease Overview 6 Therapeutics Development 7 Pipeline Products for Behcet Disease - Overview 7 Behcet Disease - Therapeutics under Development by Companies 8 Behcet Disease - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Behcet Disease - Products under Development by Companies 12 Behcet Disease - Companies Involved in Therapeutics Development 13 AbbVie Inc. 13 Celgene Corporation 14 Delenex Therapeutics AG 15 Genor BioPharma Co., Ltd. 16 HanAll Biopharma Co., Ltd. 17 Mabion SA 18 Mycenax Biotech Inc. 19 R-Pharm 20 Behcet Disease - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 adalimumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 adalimumab biosimilar - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 adalimumab biosimilar - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 apremilast - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 DLX-105 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HL-143 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 infliximab biosimilar - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 RPH-104 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Behcet Disease - Recent Pipeline Updates 45 Behcet Disease - Dormant Projects 62 Behcet Disease - Discontinued Products 63 Behcet Disease - Product Development Milestones 64 Featured News & Press Releases 64 Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 64 Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 65 Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine 65 Apr 14, 2015: Delenex Announces New Clinical Data 67 Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR 67 May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Behcet Disease, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Behcet Disease - Pipeline by AbbVie Inc., H1 2016 13 Behcet Disease - Pipeline by Celgene Corporation, H1 2016 14 Behcet Disease - Pipeline by Delenex Therapeutics AG, H1 2016 15 Behcet Disease - Pipeline by Genor BioPharma Co., Ltd., H1 2016 16 Behcet Disease - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 17 Behcet Disease - Pipeline by Mabion SA, H1 2016 18 Behcet Disease - Pipeline by Mycenax Biotech Inc., H1 2016 19 Behcet Disease - Pipeline by R-Pharm, H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Behcet Disease Therapeutics - Recent Pipeline Updates, H1 2016 45 Behcet Disease - Dormant Projects, H1 2016 62 Behcet Disease - Discontinued Products, H1 2016 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
